Raadpleeg ook literatuurlijst specifiek bij prostaatkanker van arts-bioloog drs. Engelbert Valstar. 

11 januari 2019: Bron: JAMA

Voor prostaatkanker zijn veel medicijnen en behandelingen voorhanden. Immuuntherapie wordt eigenlijk pas toegepast als alle andere al is geprobeerd. Dus in een laat stadium. Amerikaanse onderzoekers analyseerden van 1346 patiënten met prostaatkanker hun tumorexpressie en DNA mutaties. 32 van de 1033 (3,1%) bleken een zogeheten microsatellite instability–high of mismatch repair mutatie te hebben, van wie er 7 (21.9%) een kiemlijnmutatie hadden in een aan het  Lynch Syndroom gerelateerde gen (Lynch Syndroom komt ook voor bij darmkanker o.a. en wordt gezien als een erfelijke afwijking).

Uit de studie analyse bleek dat 6 van 11 patienten met een of meerdere mutaties goed reageerden op immuuntherapie met een anti-PD medicijn (bv. pembrolizumab (Keytruda) of Nivolumab) met langdurige levensverlenging. 

Zes van de 11 (54,5%) hadden een afname van meer dan 50% in PSA waarden, van wie er 4 ook door scans aangetoonde tumorvermindering hadden. In mei 2018 waren 5 van de 6 patienten (45,5 procent) die goed reageerden nog steeds onder behandeling met immuuntherapie. Zij waren toen al 89 weken in therapie.

Afbeeldingsresultaat voor images of msi unstableSource: Keytruda website

De studie: Analysis of the Prevalence of Microsatellite Instability in Prostate Cancer and Response to Immune Checkpoint Blockade is gepubliceerd in JAMA en gratis in te zien.

Hier het abstract van de studie:

December 27, 2018

Analysis of the Prevalence of Microsatellite Instability in Prostate Cancer and Response to Immune Checkpoint Blockade

JAMA Oncol. Published online December 27, 2018. doi:10.1001/jamaoncol.2018.5801

Key Points

Question  What is the prevalence of microsatellite instability in prostate cancer and its association with response to immune checkpoint blockade?

Findings  In this case series of 1346 patients with prostate cancer who underwent paired tumor and germline sequencing, 32 of 1033 (3.1%) had microsatellite instability–high or mismatch repair deficient disease, of whom 7 (21.9%) carried a germline mutation in a Lynch syndrome–associated gene. Five of 11 patients who received an anti–PD-1/PD-L1 agent had durable clinical benefit.

Meaning  The microsatellite instability–high/mismatch repair deficient phenotype is uncommon but clinically important in prostate cancer and can be somatically acquired during disease evolution.

Abstract

Importance  The anti–programmed cell death protein 1 (PD-1) antibody pembrolizumab is approved by the US Food and Drug Administration for the treatment of microsatellite instability–high (MSI-H) or mismatch repair–deficient (dMMR) solid tumors, but the prevalence of MSI-H/dMMR prostate cancer and the clinical utility of immune checkpoint blockade in this disease subset are unknown.

Objective  To define the prevalence of MSI-H/dMMR prostate cancer and the clinical benefit of anti–PD-1/programmed cell death 1 ligand 1 (PD-L1) therapy in this molecularly defined population.

Design, Setting, and Participants  In this case series, 1551 tumors from 1346 patients with prostate cancer undergoing treatment at Memorial Sloan Kettering Cancer Center were prospectively analyzed using a targeted sequencing assay from January 1, 2015, through January 31, 2018. Patients had a diagnosis of prostate cancer and consented to tumor molecular profiling when a tumor biopsy was planned or archival tissue was available. For each patient, clinical outcomes were reported, with follow-up until May 31, 2018.

Main Outcomes and Measures  Tumor mutation burden and MSIsensor score, a quantitative measure of MSI, were calculated. Mutational signature analysis and immunohistochemistry for MMR protein expression were performed in select cases.

Results  Among the 1033 patients who had adequate tumor quality for MSIsensor analysis (mean age, 65.6 [9.3] years), 32 (3.1%) had MSI-H/dMMR prostate cancer. Twenty-three of 1033 patients (2.2%) had tumors with high MSIsensor scores, and an additional 9 had indeterminate scores with evidence of dMMR. Seven of the 32 MSI-H/dMMR patients (21.9%) had a pathogenic germline mutation in a Lynch syndrome–associated gene. Six patients had more than 1 tumor analyzed, 2 of whom displayed an acquired MSI-H phenotype later in their disease course. Eleven patients with MSI-H/dMMR castration-resistant prostate cancer received anti–PD-1/PD-L1 therapy. Six of these (54.5%) had a greater than 50% decline in prostate-specific antigen levels, 4 of whom had radiographic responses. As of May 2018, 5 of the 6 responders (5 of 11 total [45.5%]) were still on therapy for as long as 89 weeks.

Conclusions and Relevance  The MSI-H/dMMR molecular phenotype is uncommon yet therapeutically meaningful in prostate cancer and can be somatically acquired during disease evolution. Given the potential for durable responses to anti–PD-1/PD-L1 therapy, these findings support the use of prospective tumor sequencing to screen all patients with advanced prostate cancer for MSI-H/dMMR. Because not all patients with the MSI-H/dMMR phenotype respond, further studies should explore mechanisms of resistance.


Plaats een reactie ...

Reageer op "Weinig patienten met prostaatkanker hebben mutaties als microsatellite instability–high (MSI-H) of mismatch repair–deficinet (dMMR)maar als ze het hebben kan immuuntherapie met anti-PD medicijnen voor langdurige levensverlenging zorgen"


Gerelateerde artikelen
 

Gerelateerde artikelen

Prostac-VF: immuuntherapie >> ProscaVax, een vaccin bestaande >> Weinig patienten met prostaatkanker >> Immuuntherapie met pembrolizumab >> Immuuntherapie voor uitgezaaide >> Provenge een immuuntherapie >> immuuntherapie met pembrolizumab >> Immuuntherapie met dendritische >> Immuuntherapie: Drie nieuwe >> Erasmus Medisch Centrum start >>